The Patent Finder

Dynavax Technologies Corporation

Also on record
Records under this name other than the patents Dynavax Technologies Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 28 patents it holds.

Back to Dynavax Technologies Corporation

PatentTitleStatus Expires Confidence
US 11,918,648Combination of a PD-1 Antagonist and Cpg-C Type Oligonucleotide for Treating Cancer
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 10,751,412Combination of a PD-1 Antagonist and Cpg-C Type Oligonucleotide for Treating Cancer
Formerly held
In force
 · High confidence
In forceHigh confidence
US 8,759,305Methods and compositions for inhibition of innate immune responses and autoimmunity
Lapsed on the fee record
Ended Jun 24, 2026 · From the USPTO record
Lapsed on the fee recordEnded Jun 24, 2026From the USPTO record
US 7,745,606Immunostimulatory sequence oligonucleotides and methods of using the same
Term ended
Term ended May 2, 2025 · From the USPTO record
Term endedTerm ended May 2, 2025From the USPTO record
US 7,255,868Chimeric immunomodulatory compounds and methods of using the same—I
Term ended
Term ended Jun 2, 2024 · From the USPTO record
Term endedTerm ended Jun 2, 2024From the USPTO record
US 9,333,254Long term disease modification using immunostimulatory oligonucleotides
Lapsed on the fee record
Ended May 10, 2024 · From the USPTO record
Lapsed on the fee recordEnded May 10, 2024From the USPTO record
US 8,114,418Chimeric immunomodulatory compounds and methods of using the same—IV
Term ended
Term ended Feb 20, 2024 · From the USPTO record
Term endedTerm ended Feb 20, 2024From the USPTO record
US 8,222,398Chimeric immunomodulatory compounds and methods of using the same-II
Term ended
Term ended Jan 16, 2024 · From the USPTO record
Term endedTerm ended Jan 16, 2024From the USPTO record
US 8,158,768Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same
Formerly held
Term ended
Term ended Dec 18, 2023 · Medium confidence
Term endedTerm ended Dec 18, 2023Medium confidence
US 8,871,732Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same
Formerly held
Term ended
Term ended Dec 18, 2023 · Medium confidence
Term endedTerm ended Dec 18, 2023Medium confidence
10 of 41 patents shown.
Pro members see all 41.
Pro members: see all 41 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited